Adimmune Corp

Chart & Performance

D1W1MN

P/E

—

P/S

5.27

EPS

—

Div Yield, %

—

Shrs. gr., 5y

3.02%

Rev. gr., 5y

3.68%

Revenues

1.56b

-12.78%

Net income

-243m

L-62.06%

CFO

668m

Dividend

Sep 14, 20210.5 TWD/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.

URL

https://www.adimmune.com.tw/

IPO date

Sep 29, 2010

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title TWD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title TWD in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT